Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYNJ2 | O15056 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | BACE1 | P56817 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | APEX1 | P27695 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | ALPL | P05186 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | SNCA | P37840 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938778 | 1.00 | SYNJ2 (0.59) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL17938831 | 0.91 | SYNJ2 (0.49) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL30217486 | 0.91 | SYNJ2 (0.49) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL350730 | 0.91 | KDM1A (0.51) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL30217524 | 0.90 | SYNJ2 (0.60) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL30933022 | 0.87 | PTGS1 (0.61) | SYNJ2KDM4EBACE1HSD17B10ALDH1A1 | |
| SCHEMBL17534890 | 0.87 | BACE1 (0.59) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL14700137 | 0.87 | BACE1 (0.59) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL17548765 | 0.87 | BACE1 (0.59) | SYNJ2KDM4EBACE1HSD17B10GAA | |
| SCHEMBL26485985 | 0.86 | BACE1 (0.60) | SYNJ2KDM4EBACE1HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009135918-A1 | COMPOSITIONS AND PROCESSES FOR PREPARING THEM | CORESSENCE LIMITED (GB) | 2009-11-12 | — | — | WO | claimed |
| US-20120015053-A1 | TREATMENT OF PSORIASIS | SCHMITZ HAROLD H (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110257119-A1 | Microcirculation improvement and/or treatment | SCHMITZ HAROLD | 2011-10-20 | — | — | US | disclosed |
| WO-2009135918-A1 | COMPOSITIONS AND PROCESSES FOR PREPARING THEM | CORESSENCE LIMITED (GB) | 2009-11-12 | — | — | WO | disclosed |
| EP-2068941-A2 | IMPROVEMENT OF ARGINASE LEVELS/ACTIVITY | Mars Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080090898-A1 | Boosting immunity | MARS, INCORPORATED (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080021097-A1 | Arginase levels/activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2008-01-24 | — | — | US | disclosed |
| WO-2008011173-A2 | IMPROVEMENT OF ARGINASE LEVELS/ACTIVITY | MARS, INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20060293259-A1 | Compositions and methods of use of derivatized flavanols | MARS, INCORPORATED (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015053-A1 | TREATMENT OF PSORIASIS | ARG1, ARG2, NOS2 | SYNJ2 2676/4885KDM4E 920/4885BACE1 1793/4885 |
| US-20110257119-A1 | Microcirculation improvement and/or treatment | TEK, SLC2A4, SLC2A8 | SYNJ2 2026/4885KDM4E 2789/4885BACE1 4534/4885 |
| US-20080090898-A1 | Boosting immunity | TLR7, TLR1, MYD88 | SYNJ2 2909/4885KDM4E 2078/4885BACE1 3547/4885 |
| US-20080021097-A1 | Arginase levels/activity | ARG1, ARG2, MPO | SYNJ2 3221/4885KDM4E 1893/4885BACE1 1803/4885 |
| US-20060293259-A1 | Compositions and methods of use of derivatized flavanols | F2, PIGS, PIGO | SYNJ2 701/4885KDM4E 428/4885BACE1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.